Creative Medical Technology (NASDAQ:CELZ) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Creative Medical Technology (NASDAQ:CELZ) from a sell rating to a hold rating in a report released on Saturday,Wall Street Zen reports.

Several other equities research analysts have also recently issued reports on CELZ. Weiss Ratings cut shares of Creative Medical Technology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, August 27th. Roth Capital reissued a “buy” rating on shares of Creative Medical Technology in a research note on Thursday, August 20th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Creative Medical Technology currently has an average rating of “Hold”.

Creative Medical Technology Price Performance

Shares of Creative Medical Technology stock opened at $0.88 on Friday. The stock has a market capitalization of $5.79 million, a P/E ratio of -0.42 and a beta of 2.04. The business has a 50 day simple moving average of $1.00 and a two-hundred day simple moving average of $1.68. Creative Medical Technology has a 12 month low of $0.62 and a 12 month high of $6.25.

Creative Medical Technology (NASDAQ:CELZ) last issued its quarterly earnings results on Friday, August 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02). As a group, research analysts anticipate that Creative Medical Technology will post -1.18 EPS for the current fiscal year.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical‐stage biotechnology company focused on the development, manufacture and commercialization of exosome‐based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti‐inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell‐free exosome formulations designed to support tissue repair and cellular rejuvenation.

The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.